Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$TGTX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.05 down -73.68% YoY • Reported revenue of $240.34M up 70.27% YoY • TG Therapeutics raised its full year 2026 total global revenue target to approximately $950 million and BRIUMVI U.S. net product revenue target to approximately $890 - $905 million for the company.
2
11

Price since post

Full Details
Top Replies
8n8or
Of course Net Income dropped with increased R&D. R&D has significant depreciation implications which is a non cash expense. This is a sign of growth. Why are people selling!😂
1
Thestockman22
Big bonus for Mike if they surpass $1B in revenue for 26
1

Advertisement|Remove ads.